| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
780,776 |
1,206,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,635,429 |
$9,420,070 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
19 |
37 |
60 |
105 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Williams Laura A |
Chief Medical Officer |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$37,446 |
D/D |
(4,794) |
367,152 |
|
13% |
|
| Raab Michael |
President & CEO |
• • – |
2024-05-21 |
4 |
S |
$7.81 |
$245,922 |
D/D |
(31,484) |
1,277,773 |
|
13% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$40,359 |
D/D |
(5,167) |
300,546 |
|
13% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$17,169 |
I/I |
(2,198) |
176,374 |
|
13% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$37,922 |
D/D |
(4,855) |
376,479 |
|
13% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$54,107 |
D/D |
(6,927) |
199,469 |
|
13% |
|
| Blanks Robert |
See Remarks |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$37,922 |
D/D |
(4,855) |
362,331 |
|
13% |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$27,221 |
D/D |
(3,485) |
95,127 |
|
13% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2024-05-21 |
4 |
S |
$7.81 |
$52,357 |
D/D |
(6,703) |
449,092 |
|
13% |
|
| Raab Michael |
President & CEO |
• • – |
2024-05-14 |
4 |
AS |
$7.99 |
$23,970 |
D/D |
(3,000) |
1,307,933 |
|
-13% |
|
| Grammer Elizabeth A |
See Remarks |
• • – |
2024-05-06 |
4 |
S |
$8.87 |
$2,522,217 |
D/D |
(284,170) |
203,760 |
|
26% |
|
| Grammer Elizabeth A |
See Remarks |
• • – |
2024-05-06 |
4 |
OE |
$0.99 |
$410,787 |
D/D |
219,937 |
487,930 |
|
- |
|
| Felsch Robert Ora |
See Remarks |
• • – |
2024-05-06 |
4 |
S |
$8.80 |
$1,831,503 |
D/D |
(207,988) |
95,947 |
|
26% |
|
| Felsch Robert Ora |
See Remarks |
• • – |
2024-05-06 |
4 |
OE |
$0.84 |
$176,445 |
D/D |
119,101 |
303,935 |
|
- |
|
| Williams Laura A |
Chief Medical Officer |
• • – |
2024-05-03 |
4 |
AS |
$8.35 |
$333,574 |
D/D |
(39,949) |
370,189 |
|
-23% |
|
| Williams Laura A |
Chief Medical Officer |
• • – |
2024-05-03 |
4 |
OE |
$0.99 |
$29,700 |
D/D |
30,000 |
410,138 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• • – |
2024-05-03 |
4 |
AS |
$9.00 |
$405,000 |
D/D |
(45,000) |
267,993 |
|
-23% |
|
| Raab Michael |
President & CEO |
• • – |
2024-04-29 |
4 |
AS |
$6.40 |
$192,057 |
D/D |
(30,000) |
1,310,933 |
|
4% |
|
| Raab Michael |
President & CEO |
• • – |
2024-04-29 |
4 |
OE |
$0.99 |
$29,700 |
D/D |
30,000 |
1,340,933 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2024-04-15 |
4 |
AS |
$7.06 |
$52,924 |
D/D |
(7,500) |
1,310,933 |
|
-1% |
|
| Raab Michael |
President & CEO |
• • – |
2024-04-01 |
4 |
AS |
$7.31 |
$11,097 |
D/D |
(1,518) |
1,318,433 |
|
-9% |
|
| Kelliher Mike |
See Remarks |
• • – |
2024-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
160,000 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• • – |
2024-03-20 |
4 |
AS |
$7.73 |
$664,978 |
D/D |
(86,000) |
312,993 |
|
-13% |
|
| Blanks Robert |
See Remarks |
• • – |
2024-03-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
367,186 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• • – |
2024-02-26 |
4 |
S |
$9.20 |
$47,684 |
I/I |
(5,183) |
175,936 |
|
27% |
|
557 Records found
|
|
Page 1 of 23 |
|
|
0.69 (9.27%) 
